Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment

BJU International

Volumn 111, Issue 6, 2013, Pages 880-890

  Raynaud, Jean Pierre ^a   Gardette, Jean ^b   Rollet, Jacques ^c   Legros, Jean Jacques ^d  

^a SORBONNE UNIVERSITÉ   (France)

^b not available   (France)

^c Institut Rhône Alpin   (France)

^d UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

hypogonadism; testosterone; transdermal; treatment

Indexed keywords

ANDROSTANOLONE; ANTIBIOTIC AGENT; ESTRADIOL; PROSTATE SPECIFIC ANTIGEN; TESTOPATCH; TESTOSTERONE; TESTOSTERONE UNDECANOATE; UNCLASSIFIED DRUG;

ADULT; AGED; ANDROGEN THERAPY; APPLICATION SITE REACTION; ARTICLE; BELGIUM; BODY HEIGHT; BODY MASS; BODY WEIGHT; CANCER RISK; CANCER SCREENING; CHRONIC FATIGUE SYNDROME; DIGITAL RECTAL EXAMINATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHEMA; FLUOROIMMUNOASSAY; FRANCE; GERMANY; HUMAN; HYPOGONADISM; INTERVENTION STUDY; LABORATORY TEST; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; OPEN STUDY; PAPULE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATITIS; SKIN IRRITATION; SPAIN; TESTOSTERONE BLOOD LEVEL; TRANSDERMAL PATCH; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84876927454     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11514.x     Document Type: Article

References (31)

1. Bhasin S,. Clinical review: androgen treatment of hypogonadal men. J Clin Endocrinol Metab 1992; 74: 1221-1225
2. Burris AS, Banks SM, Carter CS, Davidson JP, Sherins RJ,. A long-term prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl 1992; 13: 297-304
3. Matsumoto AM,. Hormonal therapy of male hypogonadism. Endocrinol Metab Clin North Am 1994; 23: 857-875
4. Arver S, Dobs AS, Meikle AW, et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol 1997; 47: 727-737
5. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2670-2677
6. Wang C, Nieschlag E, Swerdloff RS, et al. ISA, ISSAM, EAU, EAA, and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Eur J Endocrinol 2008; 159: 507-514
7. Behre HM, Boymeyer J, Nieschlag E,. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched controls. Clin Endocrinol 1994; 40: 341-349
8. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism. A randomized controlled trial. JAMA 2006; 296: 2351-2361
9. Meikle AW, Mazer NA, Moellmer JF, et al. Enhanced transdermal delivery of testosterone across non scrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metabol 1992; 85: 623-628
10. Raynaud JP, Legros JJ, Rollet J, et al. Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for one year to hypogonadal men. J Steroid Biochem Molec Biol 2008; 109: 168-176
11. Rhoden EL, Morgentaler A,. Risks of testosterone replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482-492
12. Fiet J, Giton F, Belanger A, et al. Development of a highly sensitive and specific new testosterone time-resolved fluoroimmuno-assay in human serum. Steroids 2004; 69: 461-471
13. Giton F, Fiet J, Guéchot J, et al. Serum bioavailable testosterone: assayed or calculated? Clin Chem 2006; 52: 474-481
14. Giton F, Urien S, Born C, et al. Determination of bioavailable T (Non Sex Hormone Binding Globulin [SHBG]-Bound T) in a population of healthy French Men: influence of Androstenediol on T Binding to SHBG. Clin Chem 2007; 53: 2160-2168
15. Heinemann LA, Zimmermann T, Vermeulen A, Thiel C,. A new 'Aging Male's Symptoms' (AMS) rating scale. Aging Male 1999; 2: 105-114
16. Food and Drug Administration. Centre for Drug Evaluation and Research. Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products. Rockville: Guidance for industry, 1999
17. Raynaud JP, Aumonier C, Gualano V, Betea D, Beckers A,. Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men. J Steroid Biochem Mol Biol 2008; 109: 177-184
18. Raynaud JP, Augès M, Liozno L, Turlier V, Lauze C,. Adhesiveness of a new testosterone-in-adhesive matrix patch after extreme conditions. Int J Pharm 2009; 22: 28-32
19. Raynaud JP, Tichet J, Born C, et al. Aging Male Questionnaire in normal and complaining Men. J Sex Med 2008; 5: 2703-2712
20. Jordan W,. Allergy and topical irritation associated with transdermal testosterone application: a comparison of scrotal and non scrotal transdermal system. Am J Contact Dermat 1997; 8: 108-113
21. Wilson D, Kaidbey K, Boike S, Jorkasky D,. Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy. Clin Ther 1998; 20: 2992-306
22. Meikle AW, Arver S, Dobs AS, et al. Prostate size in hypogonadal men treated with a non scrotal permeation-enhanced testosterone transdermal system. Urology 1997; 49: 191-196
23. Morgentaler A, Traish AM,. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009; 55: 310-320
24. Bonne C, Raynaud JP,. Methyltrienolone, a specific ligand for cellular androgen receptors. Steroids 1975; 26: 227-232
25. Rhoden EL, A Morgentaler A,. Influence of demographic factors and biochemical characteristicson the prostate-specific antigen (PSA) response to testosterone replacement therapy. Int J Impot Res 2006; 18: 201-205
26. Raynaud JP, Colle M, Pujos-Gautraud M, Lemaire A, Auzerie J, Gardette J,. Comparison of oral versus transdermal testosterone supplementation in hypogonadal men. Horm Mol Biol Clin Invest 2010; 2: 301-309
27. Holmäng S, Mårin P, Lindstedt G, Hedelin H,. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate 1993; 23: 99-106
28. Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D Jr, Khera M,. Testosterone therapy in men with untreated prostate cancer. J Urol 2011; 185: 1256-1260
29. Gould DC, Kirby RS,. Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer? Prostate Cancer Prostate Disease 2006; 9: 14-18
30. Raynaud JP,. Testosterone deficiency syndrome: treatment and cancer risk. J Steroid Biochem Mol Biol 2009; 114: 96-105
31. Morgentaler A,. Testosterone replacement therapy and prostate cancer. Urol Clin North Am 2007; 34: 555-563